Assessing the long-term efficacy and safety of doxofylline in treating asthma
| ISRCTN | ISRCTN10030693 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10030693 |
| Secondary identifying numbers | 30,722-303C |
- Submission date
- 28/03/2019
- Registration date
- 01/04/2019
- Last edited
- 05/04/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Plain English summary of protocol
Background and study aims
Doxofylline is a drug belonging to the class methylxanthines. Doxofylline has shown similar efficacy to theophylline in asthmatic patients but with significantly fewer side effects. Recent findings from two clinical trials (DOROTHEO1 and DOROTHEO2) performed in asthmatic patients and lasting 12 weeks showed that doxofylline has a favorable efficacy and safety profile, and that this drug provides a meaningful improvement of lung function. Unlike other xanthines such as theophylline, doxofylline does not activate certain specific cellular receptors (i.e. adenosine receptors) and does not alter the movement of calcium into cells. These specific characteristics may account for the favorable safety profile of doxofylline. The the main anti-asthmatic effects of doxophylline seems to be related with its activity on intracellular enzymes (i.e. phosphodiesterases). Thus, the aim of this study is to investigate the efficacy and safety profile of doxofylline administered for long time, up to one year, in asthmatic patients.
Who can participate?
Adult (over 18 years old) asthmatic patients
What does the study involve?
All participants received for 12 months oral doxofylline 400 mg three times daily . Lung function tests were carried out at day 1 and at months 1, 3, 6, 9, and 12.
What are the possible benefits and risks of participating?
The possible benefits may include increased lung function, reduced asthma events rate, and reduced use of albuterol, leading to an overall increased asthma control. The potential risks may include the occurrence of side effects, namely gastrointestinal symptoms (nausea, vomiting, gastrointestinal distress, stomach ache), tachycardia or palpitations, insomnia, and nervousness. In any case, the overall treatment benefits would overcome the symptoms related with the side effects.
Where is the study run from?
Allergy Associates, Inc., North Dartmouth, MA (US); Allergy, Asthma & Immunology Center of Rochester, Rochester, NY (US); International Medical Technical Consultants, Inc., Prairie Village, KS (US); Advanced Allergy & Asthma, Albany, NY (US); Pulmonary Associates, Philadelphia, PA (US); Allergic Disease Associates, Philadelphia, PA (US); Doctors’ Clinic Research Center, Vero Beach, FL (US); Pharmaco Health Research Center, Austin, TX (US); Cleveland Clinic, Cleveland, OH (US); Piedmont Research Associates, Inc., Winston-Salem, NC (US); Chicago Center for Clinical Research, Chicago, IL (US); National Association for Clinical Research, Philadelphia, PA (US); Washington University School of Medicine Research Office, St. Louise, MO (US).
When is the study starting and how long is it expected to run for?
February 1992 to September 1994
Who is funding the study?
Roberts Pharmaceutical Corporation (USA)
Who is the main contact?
Dr Alberto Giraudi
alberto.giraudi@abcfarmaceutici.it
Contact information
Scientific
Via Canton Moretti, 29
Località San Bernardo Ivrea (TO)
10090
Italy
 ORCID ID |
0000-0003-0456-069X |
|---|---|
| Phone | +39 (0)125 240111 |
| alberto.giraudi@abcfarmaceutici.it |
Study information
| Study design | Multicenter, open-label, single-arm , phase III, clinical trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Home |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet |
| Scientific title | A Long-term clinical trial on the Efficacy and Safety profile of Doxofylline in Asthma: the LESDA study |
| Study acronym | LESDA |
| Study objectives | Doxofylline may have a favorable efficacy and safety profile when administered for a longer time. |
| Ethics approval(s) | Approved 19/11/1991, Northeast Medical Research Associates Institutional Review Board (49 State Road, Watuppa Building North Dartmouth, MA, USA 02747; 1-855-636-7287; study@nemra-us.com), ref: 30,722-303C-91. |
| Health condition(s) or problem(s) studied | Asthma |
| Intervention | This is a single-arm study in which asthmatic patients received doxofylline 400 mg (Maxivent 400 mg, tablets; Lot # Dox-049-11/E) three times daily (t.i.d, drug administered at 8 hr interval) administered per os. The total duration of treatment was 12 months, and the follow up lasted 13 months |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase III |
| Drug / device / biological / vaccine name(s) | Doxofylline |
| Primary outcome measure | Airway obstruction is measured using “FEV1, detected via pulmonary” function tests at day 1 and months 1, 3, 6, 9, 12. |
| Secondary outcome measures | 1. The change from baseline (T0, hour 0) in FEV1 values is measured “via pulmonary function tests” at months 1, 3, 6, 9 and 12. 2. Asthma events rate (total number of events divided by the total number of days on study medication), and albuterol use rate (total number of puffs divided by total number of days on study medication) are determined using Medication/Symptom Diaries at “months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.” 3. Safety is assessed by physical examinations, ECGs, and the recording of vital signs, laboratory test results, and adverse events “(AE) at months 1, 3, 6, 9 and 12.” 3.1. All “clinical AE” entered on the Case Report Forms (CRFs) are classified as to possible relation to study medication (not related, possibly related, definitely related, or unknown) and severity (mild, moderate, or severe). 3.2. Also recorded for each AE are the start and stop dates, the action taken (none, study medication discontinued, or treatment prescribed), and the outcome (recovered, recovered with sequelae, under treatment, deceased, unknown, or ongoing). 3.3. If a subject experiences an AE leading to withdrawal from the study, the investigator is to make an effort to have the subject return to the study centre for examination and obtain a serum sample for drug level determination. The time and date of the last dose taken is to be entered into the CRF. |
| Overall study start date | 14/09/1990 |
| Completion date | 04/06/1997 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 300 |
| Key inclusion criteria | 1. Males and non-pregnant females. 1.1. Women of childbearing potential had to use acceptable methods of birth control and have a negative prestudy serum β-hCG pregnancy test. 1.1.1. Acceptable methods of birth control were limited to vaginal or intrauterine contraceptive devices or agents and natural (postmenopausal) or surgical sterility. 2. 18 years of age or older. 3. Nonsmokers for at least 6 months before entering the study. 4. In good physical condition with a more than 1-year history of chronic, extrinsic reversible hyperreactive airway disease (asthma). 5. On screening, had a baseline FEV1 value within 50% to 80% of the predicted FEV1 value for their age and height, when immediate-release theophylline or sustained-release theophylline had been withheld for at least 24 hours. 6. On screening, at least a 15% increase in FEV1 30 minutes after administration of a standard dose (2 puffs, 180 µg) of albuterol. 7. Stable dose of inhaled corticosteroids (ICS) and/or cromolyn sodium for at least 30 days was permitted. If ICS and/or cromolyn sodium was required during the study, it was recommended that a Doxofylline baseline level be achieved (minimum, 14 days) before the administration of any additional medications. |
| Key exclusion criteria | 1. Clinically significant deviation from normal in physical examination, laboratory parameters, ECG, or chest x-ray, as evaluated by the Principal Investigator, that would have precluded the subject’s participation in the study 2. Clinically significant coexisting disease, including: 2.1. Cardiovascular disease, including a history of congestive heart failure, angina pectoris, or myocardial infarction within 1 year 2.2. Convulsive disorder 2.3. Gastrointestinal disease 2.4. Renal disease 2.5. Hepatic disease 2.6. Hematologic disease 2.7. Insulin-dependent diabetes mellitus 2.8. Nonreversible chronic pulmonary disease 2.9. Known infection with human immunodeficiency virus 2.10. Chronic obstructive pulmonary disease 3. Presence of any acute illness 4. Sensitivity to theophylline or theophylline-like agents 5. A resting heart rate of less than 50 bpm or greater than 100 bpm and/or an arterial blood pressure of less than 100/60 mmHg or greater than 140/90 mmHg when sitting 6. History of alcohol, narcotic, barbiturate, marijuana, or polydrug abuse 7. Participation in other investigational drug studies within 30 days before the start of this study, except the DOROTHEO1 (ISRCTN65297911) and DOROTHEO2 (ISRCTN22374987) that preceded this study. 8. Subjects using oral steroids or oral B2-agonists 9. Lactating females |
| Date of first enrolment | 19/02/1992 |
| Date of final enrolment | 07/09/1994 |
Locations
Countries of recruitment
- United States of America
Study participating centres
02747
United States of America
14620
United States of America
64108
United States of America
12203
United States of America
United States of America
United States of America
19107
United States of America
32960
United States of America
78705
United States of America
44113
United States of America
27103
United States of America
60634
United States of America
19114
United States of America
43617
United States of America
Sponsor information
Industry
Meridian Center II, 4 Industrial Way West
Eatontown
07724
United States of America
| Phone | +1 (908) 389-1182 |
|---|---|
| info@robertspharm.com |
Industry
Via Canton Moretti, 29
Località San Bernardo Ivrea ( TO )
10090
Italy
| Phone | +39 (0)125 240111 |
|---|---|
| alberto.giraudi@abcfarmaceutici.it | |
| Website | http://www.abcfarmaceutici.it |
Not defined
| Website | http://www.takeda.com/ |
|---|---|
"ROR" |
https://ror.org/03bygaq51 |
Funders
Funder type
Industry
No information available
No information available
Results and Publications
| Intention to publish date | 15/12/2019 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | This study is planned to be published in a high-impact peer reviewed journal by 15/12/2019. Additional documents (study protocol and clinical study report) will be publically available at the date of publication of the study. |
| IPD sharing plan | Dr Alberto Giraudi (alberto.giraudi@abcfarmaceutici.it) can be contacted for accessing to the datasets. Available data include patient-by-patient variable recorded at each time-point and will be available for request in one year from the publication of the paper. Informed consent was obtained by all the participants of the study. Data will be shared merely for scientific purposes (i.e. post-hoc analyses, pooled analyses) with researchers employed at institutional research departments who will make a formal request to the scientific board of ABC Farmaceutici. If the scientific board determine the proposed analysis is consistent with the local ethics and legal rules, and could provide further evidence than those published, the data will be released in agreement with patients' anonymisation. The data will be available for one year from the date of publication in a high-impact peer reviewed journal. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Basic results | 30/03/2019 | 01/04/2019 | No | No |
Additional files
- ISRCTN10030693_BasicResults_30Mar19.pdf
- Uploaded 01/04/2019.
Editorial Notes
05/04/2019: Internal review.
01/04/2019: Trial's existence confirmed by ABC Farmaceutici.
